These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16227677)

  • 1. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study.
    Taher A; Sheikh-Taha M; Sharara A; Inati A; Koussa S; Ellis G; Dhillon AP; Hoffbrand AV
    Acta Haematol; 2005; 114(3):146-9. PubMed ID: 16227677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S; Jabbari A; Cohan N; Haghpanah S
    Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
    Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
    J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year trial of deferiprone chelation therapy in thalassaemia major patients.
    Taher A; Aoun E; Sharara AI; Mourad F; Gharzuddine W; Koussa S; Inati A; Dhillon AP; Hoffbrand AV
    Acta Haematol; 2004; 112(4):179-83. PubMed ID: 15564727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N; Jahazi A; Rahim Abad HH
    Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
    Cohen AR; Galanello R; Piga A; De Sanctis V; Tricta F
    Blood; 2003 Sep; 102(5):1583-7. PubMed ID: 12763939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL
    Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes.
    Yusuf S; Herdata HN; Edward ED; Khairunnisa K
    F1000Res; 2023; 12():154. PubMed ID: 39233713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
    Zachariah M; Tony S; Bashir W; Al Rawas A; Wali Y; Pathare A
    Pediatr Hematol Oncol; 2013 Mar; 30(2):104-12. PubMed ID: 23363369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
    Maggio A; D'Amico G; Morabito A; Capra M; Ciaccio C; Cianciulli P; Di Gregorio F; Garozzo G; Malizia R; Magnano C; Mangiagli A; Quarta G; Rizzo M; D'Ascola DG; Rizzo A; Midiri M
    Blood Cells Mol Dis; 2002; 28(2):196-208. PubMed ID: 12064916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
    Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
    Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
    Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.